Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients.

Lankhorst, Stephanie; Baelde, Hans J; Verstijnen, Jose A M C; Ten Tije, Albert J; Thelen, Marc H M; Danser, A H Jan; van den Meiracker, Anton H; Kappers, Mariëtte H W

Lankhorst, Stephanie; Baelde, Hans J; Verstijnen, Jose A M C; Ten Tije, Albert J; Thelen, Marc H M; Danser, A H Jan; van den Meiracker, Anton H; Kappers, Mariëtte H W.

Afiliação

Lankhorst S; Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Baelde HJ; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Verstijnen JAMC; Department of Oncology, Amphia Hospital, Breda, The Netherlands; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
Ten Tije AJ; Department of Oncology, Amphia Hospital, Breda, The Netherlands.
Thelen MHM; Clinical Chemical Laboratory, Amphia Hospital, Breda, The Netherlands.
Danser AHJ; Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
van den Meiracker AH; Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Kappers MHW; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands. Electronic address: MKappers@amphia.nl.

J Am Soc Hypertens ; 12(11): e1-e7, 2018 11.

Article em En | MEDLINE | ID: mdl-29960864

Palavras-chave

Albuminuria; angiogenesis inhibition; nephrinuria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: J Am Soc Hypertens Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google